New study tests early migraine drug to halt pain before it begins

NCT ID NCT07310290

Recruiting now Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 19, 2026 · Updated 24 times

Summary

This study looks at whether taking ubrogepant during the earliest signs of a migraine (called prodrome) can prevent the headache from becoming moderate or severe. About 189 adults with 4-10 migraine days per month will take the drug as prescribed by their doctor and track their symptoms for up to 13 weeks. The goal is to see if early treatment can stop the worst pain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chicago Headache Center & Research Inst /ID# 272345
RECRUITING

Naperville, Illinois, 60563, United States
Neurology and Pain Specialty Center /ID# 278508
RECRUITING

Aliso Viejo, California, 92656, United States
Tri City Research Center, LLC /ID# 278800
RECRUITING

Grand Island, Nebraska, 68803, United States

Conditions

Explore the condition pages connected to this study.

MIGRAINE